USP22 and pancreatic neoplasm: In addition, an in vitro study using pancreatic cancer cells showed that downregulation of USP22 reduced cell stemness and enhanced drug sensitivity by inactivating the Wnt/β‐catenin pathway (Li et al. 2022).